Transition Therapeutics Inc (TTHI.OQ) Key Developments | Reuters.com
Edition:
United States

Transition Therapeutics Inc (TTHI.OQ)

TTHI.OQ on NASDAQ Stock Exchange Global Market

0.71USD
2:37pm EDT
Change (% chg)

$-0.03 (-4.05%)
Prev Close
$0.74
Open
$0.73
Day's High
$0.73
Day's Low
$0.71
Volume
6,700
Avg. Vol
6,396
52-wk High
$2.74
52-wk Low
$0.71

Latest Key Developments (Source: Significant Developments)

Transition Therapeutics Q3 loss per share C$0.11
Wednesday, 11 May 2016 04:16pm EDT 

Transition Therapeutics Inc :Q3 loss per share C$0.11.  Full Article

Transition Therapeutics reports Q3 loss per share $0.11
Wednesday, 11 May 2016 04:01pm EDT 

Transition Therapeutics Inc : Q3 loss per share $0.11 .Existing cash resources should enable co to execute business plan and meet projected cash requirements beyond next 12 months.  Full Article

Transition Therapeutics Inc announces top line phase 2 Clinical Study Results of Diabetes Drug Candidate TT401
Monday, 1 Feb 2016 06:01am EST 

Transition Therapeutics Inc:Announced the results of a Phase 2 clinical study of drug candidate TT401 (LY2944876) for the treatment of type 2 diabetes.Says TT401 is a once-weekly administered oxyntomodulin analog with dual GLP-1 and glucagon agonist activity.All TT401 dose arms and the exenatide arm were statistically significant relative to the placebo arm at weeks 12 and 24.  Full Article

Transition Therapeutics Inc announces agreement for phase 2 Study of TT701 Drug Candidate
Thursday, 29 Oct 2015 04:01pm EDT 

Transition Therapeutics Inc:Transition Therapeutics Ireland Limited ("TTIL") has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital (BWH).TTIL will support a Phase 2 study to evaluate selective androgen receptor modulator (SARM) drug candidate TT701 as a therapy to improve the symptoms of androgen deficiency in men with prostate cancer who have undergone a radical prostatectomy procedure.  Full Article

Transition Therapeutics says Alzheimer's drug effective in sub-group
Thursday, 15 Oct 2015 06:01am EDT 

Transition Therapeutics:Announces results of data analysis from elnd005 phase 2/3 clinical study in agitation and aggression in alzheimer's disease patients.Says primary efficacy endpoint not achieved in overall study.Says elnd005 demonstrated acceptable safety and tolerability profile.Says elnd005 was shown to have an acceptable safety and tolerability profile in the study.Says company intends to meet with regulators to seek guidance on elnd005 phase 3 program.  Full Article

Transition Therapeutics announces results of clinical study of ELND005
Wednesday, 24 Jun 2015 06:01am EDT 

Transition Therapeutics:Announces results of clinical study of elnd005 in agitation and aggression in patients with alzheimer's disease.Phase 2/3 clinical study of neuropsychiatric drug candidate elnd005 did not meet its primary efficacy endpoint.Both treatment and placebo groups showed significant, but similar, reduction in agitation and aggression relative to baseline.  Full Article

Transition Therapeutics Inc appoints Carl Damiani as President
Tuesday, 16 Jun 2015 06:01am EDT 

Transition Therapeutics Inc:Appoints Carl Damiani as President and Chief Operating Officer of Transition.  Full Article

Transition Therapeutics announces results from phase 1 AME & Renal clearance clinical studies of neuropsychiatric drug candidate ELND005
Thursday, 26 Mar 2015 06:01am EDT 

Transition Therapeutics Inc:Announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005.These studies, an absorption-metabolism-excretion (AME) study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration (FDA) for the approval of most drugs in development.Says the AME study enrolled 8 subjects and the renal clearance study enrolled 42 subjects.Says in both studies, ELND005 showed good safety and tolerability.The key result of the AME study was that ELND005 showed good oral bioavailability as there was nearly 100 pct absorption.ELND005 showed no evidence of hepatic or intermediary metabolism and the study demonstrated that the main excretion route of ELND005 is via the kidney.  Full Article

Transition Therapeutics Inc announces closing of public offering of $23 mln of common shares
Wednesday, 18 Feb 2015 04:01pm EST 

Transition Therapeutics Inc:Announced the closing of its underwritten public offering of an aggregate of 3,538,461 common shares at a price to the public of $6.50 per share, including 461,538 common shares issued upon the exercise of the underwriters' over-allotment option.Cowen and Company, LLC was the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC were the co-managers for the offering.Expects to use the net proceeds from the sale of the common shares for general corporate purposes, including expenditures related to the advancement of the Company's drug candidates through the various clinical trial phases.  Full Article

Transition Therapeutics Inc announces pricing of public offering of $20 million of common shares
Thursday, 12 Feb 2015 08:00am EST 

Transition Therapeutics Inc:Says pricing of its underwritten public offering of 3,076,923 common shares at a price to the public of US$6.50 per share for total gross proceeds of $20 million.Company has granted the underwriters a 30-day option to purchase up to an additional 461,538 common shares, which could result in an additional $3 million of gross proceeds.The offering is expected to close on Feb. 18, subject to customary closing conditions.Says Cowen and Company, LLC is the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC are the co-managers for the offering.Company expects to use net proceeds from the sale of the common shares for general corporate purposes, including expenditures related to the advancement of the Company's drug candidates through the various clinical trial phases.  Full Article

BRIEF-Transition Therapeutics reports Q3 loss per share $0.11

* Existing cash resources should enable co to execute business plan and meet projected cash requirements beyond next 12 months Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)